<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740723</url>
  </required_header>
  <id_info>
    <org_study_id>1880</org_study_id>
    <nct_id>NCT04740723</nct_id>
  </id_info>
  <brief_title>Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension</brief_title>
  <acronym>RADAR</acronym>
  <official_title>A Renal Artery Denervation Feasibility Study of the MetAvention Integrated Radio Frequency Denervation System for the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metavention</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metavention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety of renal denervation using the iRF&#xD;
      System and to understand any potential improvement in hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, multi-center, non-randomized trial to evaluate the&#xD;
      initial safety and performance of renal denervation with the iRF system for the treatment of&#xD;
      hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a prospective, single-arm, multi-center, non-randomized feasibility trial</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Major Adverse Events</measure>
    <time_frame>Index Procedure through 30 days</time_frame>
    <description>Incidence of the following Major Adverse Events (MAEs)&#xD;
Death (all-cause)&#xD;
New onset end stage renal disease&#xD;
Significant embolic events resulting in end-organ damage&#xD;
Renal artery perforation or dissection requiring intervention&#xD;
Hospital admission for hypertensive crisis not related to confirmed non-adherence with medications or protocol&#xD;
New renal stenosis &gt; 70 %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic/Diastolic Blood Pressure - Average Automated Office Blood Pressure</measure>
    <time_frame>Time Frame: 30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in systolic/diastolic blood pressure as indicated by average automated office blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Time Frame: 90, 180 and 365 days</time_frame>
    <description>Change from baseline in systolic/diastolic blood pressure as indicated by ambulatory blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on renal function assessed with glomerular filtration rate</measure>
    <time_frame>Time Frame: 30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in renal function as indicated by eGFR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation with the iRF system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iRF System Renal Denervation</intervention_name>
    <description>The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery</description>
    <arm_group_label>Renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 80 years old&#xD;
&#xD;
          2. Office SBP ≥ 140 and &lt; 180 mmHg on a stable dose of antihypertensive medication(s) for&#xD;
             at least 30 days&#xD;
&#xD;
          3. Documented daytime systolic ABP ≥ 135 and &lt; 170 mmHg&#xD;
&#xD;
          4. Waist circumference ≥ 102 cm (male) and ≥ 88 cm (female)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          5. Renal artery anatomy on either side, ineligible for treatment including the following:&#xD;
&#xD;
               1. Main renal artery diameter &lt; 4.0 mm or &gt; 7.0 mm&#xD;
&#xD;
               2. Main renal artery length &lt; 20.0 mm&#xD;
&#xD;
               3. Only one functioning kidney&#xD;
&#xD;
               4. Presence of abnormal kidney tumors&#xD;
&#xD;
               5. Renal artery with aneurysm&#xD;
&#xD;
               6. Pre-existing renal stent or history of renal artery angioplasty&#xD;
&#xD;
               7. Fibromuscular disease of the renal arteries&#xD;
&#xD;
               8. Presence of renal artery stenosis of any origin ≥ 30 %&#xD;
&#xD;
               9. Individual lacks appropriate renal artery anatomy&#xD;
&#xD;
          6. Prior renal denervation procedure&#xD;
&#xD;
          7. Iliac/femoral artery stenosis precluding insertion of the iRF Catheter&#xD;
&#xD;
          8. Evidence of active infection within 7 days of the Index Procedure&#xD;
&#xD;
          9. Type 1 diabetes mellitus&#xD;
&#xD;
         10. Documented history of chronic active inflammatory bowel disorders such as Crohn&#xD;
             disease or ulcerative colitis&#xD;
&#xD;
         11. eGFR &lt; 45 mL/min per 1.73 m2&#xD;
&#xD;
         12. Brachial circumference ≥ 42 cm&#xD;
&#xD;
         13. Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and&#xD;
             cerebrovascular accident) within 6 months of patient consent&#xD;
&#xD;
         14. Myocardial infarction within 6 months of patient consent&#xD;
&#xD;
         15. Heart failure (New York Heart Association [NYHA] Class III-IV) at time of consent&#xD;
&#xD;
         16. Documented confirmed episode(s) of stable or unstable angina within 6 months of&#xD;
             patient consent&#xD;
&#xD;
         17. Documented history of persistent or permanent atrial tachyarrhythmia&#xD;
&#xD;
         18. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory&#xD;
             support for sleep apnea&#xD;
&#xD;
         19. Night shift workers&#xD;
&#xD;
         20. Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin&#xD;
             therapy is allowed.&#xD;
&#xD;
         21. Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal&#xD;
             stimulator, baroreflex stimulator)&#xD;
&#xD;
         22. Primary pulmonary HTN (&gt; 60 mmHg pulmonary artery or right ventricular systolic&#xD;
             pressure)&#xD;
&#xD;
         23. Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism,&#xD;
             coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or&#xD;
             primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism&#xD;
             are permissible.)&#xD;
&#xD;
         24. Documented contraindication or allergy to contrast medium not amenable to treatment&#xD;
&#xD;
         25. Limited life expectancy of &lt; 1 year at the discretion of the investigator&#xD;
&#xD;
         26. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to&#xD;
             comprehend or follow instructions, or for any reason in the opinion of the&#xD;
             investigator, would be unlikely or unable to comply with study protocol requirements&#xD;
             or whose participation may result in data analysis confounders (e.g., night shift&#xD;
             workers)&#xD;
&#xD;
         27. Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test&#xD;
             result required documented within a maximum of 7 days before procedure for all women&#xD;
             of childbearing potential)&#xD;
&#xD;
         28. Concurrent enrollment in any other investigational drug or device trial (participation&#xD;
             in noninterventional registries is acceptable)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Ahlstrom</last_name>
    <phone>612-814-8208</phone>
    <email>aahlstrom@metavention.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Israeli-Georgian Medical Research Clinic Helsicore</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

